B DayToday

               To Be or Not to Be that is the Question?
                                                                     No it is Not!

                       The Question is Does Getting Rid of the B cells
Inhibit Progressive MS Independent of Getting Rid of Active Inflammation

so
To (Deplete) B or Not to (Deplete) B that is the Question
(for PPMS)

Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial

Maybe ProfG can post the Answer Apres-ski as I am sure he knows as one of the collaborators

Alternatively Why Not Tweet the Answer.
The Talk is Today.

I suspect the answer is going to be that it does not matter, 
but that would rewrite the history of anti-inflammatories in PPMS
including the rituximab in PPMS conclusion.
We will See. 

Labels: